Island Pharmaceuticals Ltd (ILA)

Snapshot

ILA's Principal Activity is the drug research and repurposing

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr David Lionel Brookes	Non-Executive Director	Oct 2020	Dr David Lionel Brookes Non-Executive Director Dr Brookes has experience in the health and biotechnology industries and has held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI ) in June 2018. He is currently the non-executive Chairman of ASX listed Factor Therapeutics Ltd and of Anatara Lifesciences Ltd . He is currently a non-executive director of ASX listed company TALi Digital Ltd and is the chair of the Audit & Risk committee
Dr David Foster	Managing Director	Oct 2020	Dr David Foster Managing Director Dr Foster has vast experience in the life science industry including 20+ years representing diverse companies, such as pharmaceutical, biotherapeutic and diagnostic companies while in private legal practice. In addition, he served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb. Dr Foster co-founded Roberts Foster LLP- a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies. He is a Board member of bionorthTx and private biotechnology companies. Dr Foster has expertise in formulating intellectual property and business strategies to protect and develop therapeutic assets.
Mr Albert Hansen	Non-Executive Director	Oct 2020	Mr Albert Hansen Non-Executive Director Mr Hansen is currently President of KESA Partners, Inc. (KESA) a family investment office focused on seed investing in life science-related startups. KESA provides capital and strategic management to its portfolio companies. Mr. Hansen serves as President of one of KESA's portfolio companies, Clearlight Biotechnologies, Inc., which has licensed imaging technology for tissue analysis from Stanford University. From 2001 to 2012, Mr. Hansen was a Managing Director of Signet Healthcare Partners, a growth capital private equity firm focused on emerging life science companies. Mr. Hansen has over 25 years of private equity investment experience, with almost 20 years in the life sciences/pharmaceutical field. He is a former Chairman and interim CEO of Questcor Pharmaceuticals, Inc (later acquired for US$5 billion), a former Chairman and interim CEO of Cedarburg Pharmaceuticals Inc. (acquired for US$40 million) and former Chairman of Molecular Medicine Corporation (acquired for US$24 million). KESA Partners, Inc acquired a failing company, Bioserv Corporation, for US$25,000 from NextPharma, Ltd in November 2012. He has also been a director of over ten other private companies. Prior to Signet, Mr Hansen was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also a political appointee as Director of Corporate Finance at the U.S. Treasury Department in 1992. Earlier in his career, Mr Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr Hansen also served in the U.S. Army as an Infantry and Special Forces office
Dr Anna Lavelle	Non-Executive Director	Oct 2020	Dr Anna Lavelle Non-Executive Director Dr Lavelle is an experienced Non-Executive Director serving for over 25 years on the boards of not for profit, government and for profit entities. As Executive Director or Non-Executive Director she has a lengthy track record in healthcare delivery, technology development and negotiating government policy. In 2015 Nature Scientific America, World View ranked Dr Lavelle in the global top 100 "World Visionaries" in biotechnology. Dr Lavelle was the only Australian to be named. From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including - Independent Chair, Medicines Australia Ltd, Independent Chair, Avatar Brokers Pty Ltd, Non- Executive Director Hemideina Pty Ltd, NonExecutive Director Cyban Pty Ltd
Dr Paul MacLeman	Executive Chairman,Executive Director	May 2020	Dr Paul MacLeman Executive Chairman,Executive Director Dr MacLeman has over 25 years' experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Dr MacLeman has expertise in capital raising, business development, technology commercialisation and sales & marketing globally. Dr MacLeman has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Dr MacLeman has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Dr MacLeman is currently Chairman of AdAlta Limited (1AD:ASX), Chairman of SuperTrans Medical Limited and nonexecutive director of Upkara Inc. & Upkara Asia Pacific Pty Ltd. Dr MacLeman Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an expert advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Dr MacLeman also serves on a number of other NFP and government advisory groups.
Mr Peter Webse	Company Secretary	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Anna Lavelle	30/06/2021	N/A	N/A	400,000	N/A
Albert Hansen	30/06/2021	N/A	10,837,367	423,030	N/A
David Foster	30/06/2021	5,146,829	64,564	533,333	N/A
David Brookes	30/06/2021	N/A	N/A	400,000	N/A
Paul MacLeman	30/06/2021	1	85,053	2,325,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Dr William James Garner	21,090,605	26.05%
Kesa Partners Inc	10,837,367	13.38%
Dr David C Foster	5,146,829	6.36%
Mr Jason Alan Carroll	4,050,000	5.00%
Manchester Explorer Lp	3,774,139	4.66%
Mr Andre Fraga Figueiredo	1,747,947	2.16%
Jeb Partners Lp	1,511,322	1.87%
Mr Phillip Richard Perry	1,210,000	1.49%
BNP Paribas Nominees Pty Ltd- Ib Au Noms Retailclient Drp	971,007	1.20%
Mr Richard M Hemry	679,340	0.84%
Mrs Patricia Fernandes Dias De Almeida	660,861	0.82%
Citicorp Nominees Pty Limited	625,441	0.77%
Mr Alistair Robert Baker	557,537	0.69%
Dr William James Garner I	556,397	0.69%
Mrs Azam Mohsenin-Moshiri	500,000	0.62%
Dr Daniel Tillett	495,918	0.61%
National Nominees Limited	475,000	0.59%
Pac Partners Securities Pty Ltd	440,000	0.54%
Gor Zhirar Karapetyan	407,604	0.50%
Ayers Capital Pty Ltd	405,283	0.50%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

ILA Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.